SUTRO BIOPHARMA, INC. (STRO) research
SUTRO BIOPHARMA, INC.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $15.71
- As of
SUTRO BIOPHARMA, INC. (STRO): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-12.
As of . Source: SEC EDGAR filings for STRO. Method and limitations.
Share the STRO intelligence card
See STRO live in the terminal
Track STRO's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live STRO terminal, freeActive signals for STRO
- highCONSENSUS_BUY
3 tracked funds increased STRO this 2026Q2, institutional consensus
- highCONSENSUS_BUY
4 tracked funds increased STRO this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 66% of STRO (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +74% to STRO (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +218% to STRO (2026Q2)
FREE, NO ACCOUNT
Every signal on STRO, as it fires
You are seeing 5 of 29 signals recorded on STRO since 2026-05-24.
The five above landed across 2 days. The other 24 were recorded on 3 other days. 20 of the 29 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in STRO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 869367201 · 2026Q2 | $12.2M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 869367201 · 2026Q2 | $7.9M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 869367201 · 2026Q2 | $6.7M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 869367201 · 2026Q2 | $3.4M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 869367201 · 2026Q2 | $2.9M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 869367201 · 2026Q2 | $1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, STRO
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
STRO mentioned in Kresmion daily briefs
STRO against its peers
STRO's operating margin of -154.5% ranks in the 54th percentile of 13 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.
| Metric | STRO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 102M USD | 31.4M USD | 75 | 17 |
| Operating margin | -154.5% | -154.7% | 54 | 13 |
| Net margin | -186.5% | -141.4% | 43 | 14 |
| Return on equity | n/a | -50.5% | n/a | 22 |
Peers (23): EYPT, IPSC, SION, CMPX, SABS, LXEO, ABEO, EVMN, EBS, QTTB, IFRX, ENTA, XFOR, VNDA, IKT, OCGN, OBIO, FATE, DMAC, RZLT, RCKT, MYGN, ZNTL. Left out: VCRE (no annual filing), CUVL (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (STRO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more STRO signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to STROand get the insider, 13F, options, and confluence read in one view.